New drug aims to control advanced cervical cancer
NCT ID NCT05475171
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorigerlimab (MGD019), a drug given by IV
What this could lead to
If it works, this could offer a new treatment option to help control advanced cervical cancer and improve survival.
What could go wrong
This is a small, early-phase trial that is currently suspended. It may not show benefit, and immunotherapy can cause side effects like inflammation in healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States